ZVRA

$0.00

(

+0.00%

)
Quote details

stock

Zevra Therapeutics Inc.

NASDAQ | ZVRA

9.77

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 26, 2025)

$534.41M

Market Cap

-

P/E Ratio

-0.25

EPS

$13.16

52 Week High

$6.19

52 Week Low

HEALTHCARE

Sector

ZVRA Chart

Recent Chart
Price Action

ZVRA Technicals

Tags:

ZVRA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $16M
Total Revenue $24M
Cost Of Revenue $7.4M
Costof Goods And Services Sold $7.4M
Operating Income -$87M
Selling General And Administrative $55M
Research And Development $42M
Operating Expenses $103M
Investment Income Net -
Net Interest Income -$5.2M
Interest Income $2.2M
Interest Expense $7.4M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $6.4M
Income Before Tax -$90M
Income Tax Expense $15M
Interest And Debt Expense -
Net Income From Continuing Operations -$106M
Comprehensive Income Net Of Tax -
Ebit -$83M
Ebitda -$76M
Net Income -$106M

Revenue & Profitability

Earnings Performance

ZVRA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $178M
Total Current Assets $86M
Cash And Cash Equivalents At Carrying Value $34M
Cash And Short Term Investments $34M
Inventory $2M
Current Net Receivables $11M
Total Non Current Assets $92M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $69M
Intangible Assets Excluding Goodwill $69M
Goodwill $4.7M
Investments -
Long Term Investments $6M
Short Term Investments $36M
Other Current Assets $4.1M
Other Non Current Assets -
Total Liabilities $138M
Total Current Liabilities $34M
Current Accounts Payable $13M
Deferred Revenue -
Current Debt -
Short Term Debt $420K
Total Non Current Liabilities $104M
Capital Lease Obligations $792K
Long Term Debt $60M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $60M
Other Current Liabilities $6.1M
Other Non Current Liabilities $12M
Total Shareholder Equity $40M
Treasury Stock -
Retained Earnings -$505M
Common Stock $5K
Common Stock Shares Outstanding $46M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$70M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $6.4M
Capital Expenditures $0
Change In Receivables -
Change In Inventory -$8.9M
Profit Loss -
Cashflow From Investment -$22M
Cashflow From Financing $82M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $0
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$106M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $16M
Total Revenue $24M
Cost Of Revenue $7.4M
Costof Goods And Services Sold $7.4M
Operating Income -$87M
Selling General And Administrative $55M
Research And Development $42M
Operating Expenses $103M
Investment Income Net -
Net Interest Income -$5.2M
Interest Income $2.2M
Interest Expense $7.4M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $6.4M
Income Before Tax -$90M
Income Tax Expense $15M
Interest And Debt Expense -
Net Income From Continuing Operations -$106M
Comprehensive Income Net Of Tax -
Ebit -$83M
Ebitda -$76M
Net Income -$106M

ZVRA News

ZVRA Profile

Zevra Therapeutics Inc. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Zevra Therapeutics, Inc. is a leading biopharmaceutical company focused on addressing the unmet medical needs in rare diseases through its innovative prodrug development platform. Headquartered in Celebration, Florida, Zevra is committed to advancing therapies for serious conditions, leveraging its proprietary technology to enhance drug efficacy and patient outcomes. With a dedicated pipeline and a strategic emphasis on rare diseases, Zevra is poised to make significant contributions to the healthcare landscape.

DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
BIAF
+55.13%
$5.29
RGTI
-2.86%
$31.18
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.79%
$3.18
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
BBD
-2.09%
$3.27
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
LYT
-16.77%
$0.09
AMZN
-0.93%
$218.15
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
SOUN
-2.50%
$15.94
PLTR
-0.86%
$177.57
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
FCX
+1.14%
$35.74
BURU
-10.14%
$0.12
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
ETHD
-5.95%
$3.95
IXHL
-0.01%
$0.59
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RR
+2.68%
$4.20
CLSK
-5.32%
$13.68
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
RAYA
-3.15%
$0.04
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.52%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
HBAN
+0.57%
$17.42
ORCL
-2.70%
$283.45
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
AIIO
-15.63%
$2.04
NWTN
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
BIAF
+55.13%
$5.29
RGTI
-2.86%
$31.18
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.79%
$3.18
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
BBD
-2.09%
$3.27
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
LYT
-16.77%
$0.09
AMZN
-0.93%
$218.15
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
SOUN
-2.50%
$15.94
PLTR
-0.86%
$177.57
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
FCX
+1.14%
$35.74
BURU
-10.14%
$0.12
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
ETHD
-5.95%
$3.95
IXHL
-0.01%
$0.59
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RR
+2.68%
$4.20
CLSK
-5.32%
$13.68
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
RAYA
-3.15%
$0.04
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.52%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
HBAN
+0.57%
$17.42
ORCL
-2.70%
$283.45
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
AIIO
-15.63%
$2.04
NWTN
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.